<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764774</url>
  </required_header>
  <id_info>
    <org_study_id>17110</org_study_id>
    <secondary_id>J1D-MC-GZAA</secondary_id>
    <nct_id>NCT03764774</nct_id>
  </id_info>
  <brief_title>A Study of LY3463251 in Healthy Participants</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Subject- and Investigator-Blind, Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetics Study of LY3463251 in Healthy and Overweight Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability (side effects) of single
      (Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously
      (under the skin) into the abdomen.

      This is a two-part study. Participants will enroll in only one part. For each participant,
      Part A will last about 10 weeks and Part B will last about 23 weeks, including screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">April 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through follow up in Part A (up to Day 42); Baseline through follow up in Part B (up to Day 123)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3463251</measure>
    <time_frame>Baseline to Day 29 (Part A); Baseline to Day 107 (Part B)</time_frame>
    <description>PK: Cmax of LY3463251</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3463251</measure>
    <time_frame>Baseline to Day 29 (Part A); Baseline to Day 107(Part B)</time_frame>
    <description>PK: AUC of LY3463251</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): AUC of glucose</measure>
    <time_frame>Baseline to Day 85 (Part B)</time_frame>
    <description>PD: AUC of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, Day 85 (Part B)</time_frame>
    <description>Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3463251 Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3463251 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3463251 Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3463251 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Multiple Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3463251</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3463251 Multiple Dose</arm_group_label>
    <arm_group_label>LY3463251 Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo Multiple Dose</arm_group_label>
    <arm_group_label>Placebo Single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females

        Exclusion Criteria:

          -  Diagnosed with Type 1 or Type 2 diabetes

          -  Women who are of childbearing potential or who are breastfeeding

          -  Donated blood of more than 500 millilitres (mL) within the previous 3 months of study
             screening

          -  Have used any tobacco product within 3 months of Day -1, or are unwilling to refrain
             from the use of tobacco during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>386-257-5717</phone>
    </contact>
    <investigator>
      <last_name>Lawrence A Galitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

